Several population-based cohort studies have explored the association between sodium–glucose cotransporter 2 (SGLT2) inhibitors and the risk of dementia in patients with type 2 diabetes mellitus (T2DM), revealing their potential neuroprotective effects. Here, SLC5A2 is linked to type 2 diabetes mellitus.